{
  "description": "Validated cross-category drug repurposing patterns from h191 analysis and literature validation",
  "created": "2026-02-05",
  "hypothesis_source": "h194",
  "validation_method": "Literature search via PubMed, FDA approvals, clinical guidelines",
  "patterns": [
    {
      "id": "crp_001",
      "atc_category": "C:cardiovascular",
      "disease_category": "metabolic",
      "drug_classes": ["Statins (HMG-CoA reductase inhibitors)", "Fibrates"],
      "example_drugs": ["Lovastatin", "Gemfibrozil", "Atorvastatin", "Rosuvastatin"],
      "mechanism": "Statins lower LDL cholesterol and reduce cardiovascular risk in metabolic syndrome patients",
      "validation_status": "FDA_APPROVED",
      "evidence": [
        "Statins are standard of care for cardiovascular risk reduction in diabetes (ADA Standards 2024)",
        "SGLT2 inhibitors + statins are first-line for cardiometabolic disease",
        "Fibrates reduce triglycerides in metabolic syndrome"
      ],
      "hits_in_model": 20,
      "confidence": "high"
    },
    {
      "id": "crp_002",
      "atc_category": "J:antiinfectives_systemic",
      "disease_category": "respiratory",
      "drug_classes": ["Macrolide antibiotics", "Fluoroquinolones"],
      "example_drugs": ["Azithromycin", "Levofloxacin"],
      "mechanism": "Anti-inflammatory effects independent of antimicrobial activity; modulates cytokines, reduces neutrophil infiltration",
      "validation_status": "VALIDATED_TRIALS",
      "evidence": [
        "NEJM 2011: Azithromycin reduces COPD exacerbations by 27%",
        "Azithromycin inhibits MUC5AC via ERK1/2 pathway",
        "Subantibiotic doses have anti-inflammatory effects"
      ],
      "hits_in_model": 19,
      "confidence": "high"
    },
    {
      "id": "crp_003",
      "atc_category": "H:systemic_hormonal",
      "disease_category": "respiratory",
      "drug_classes": ["Corticosteroids"],
      "example_drugs": ["Methylprednisolone", "Prednisone", "Hydrocortisone"],
      "mechanism": "Anti-inflammatory effects on airway inflammation; standard treatment for asthma and COPD exacerbations",
      "validation_status": "FDA_APPROVED",
      "evidence": [
        "Corticosteroids are guideline-recommended for asthma and COPD",
        "Multiple ATC codes (H, D, S) due to different formulations"
      ],
      "hits_in_model": 17,
      "confidence": "high"
    },
    {
      "id": "crp_004",
      "atc_category": "A:alimentary_tract_metabolism",
      "disease_category": "cardiovascular",
      "drug_classes": ["SGLT2 inhibitors", "GLP-1 receptor agonists"],
      "example_drugs": ["Empagliflozin", "Canagliflozin", "Semaglutide"],
      "mechanism": "Originally for diabetes, now first-line for heart failure due to cardiorenal benefits",
      "validation_status": "FDA_APPROVED",
      "evidence": [
        "EMPA-REG OUTCOME: 35% reduction in HF hospitalization",
        "Empagliflozin (Jardiance) FDA approved for HFrEF and HFpEF",
        "CREDENCE, DAPA-CKD trials showed cardiorenal benefits",
        "Wegovy (semaglutide) FDA approved for CV risk reduction (March 2024)"
      ],
      "hits_in_model": 7,
      "confidence": "high"
    },
    {
      "id": "crp_005",
      "atc_category": "A:alimentary_tract_metabolism",
      "disease_category": "dermatological",
      "drug_classes": ["Tetracyclines"],
      "example_drugs": ["Doxycycline"],
      "mechanism": "Anti-inflammatory effects via MMP inhibition, cytokine modulation; treats acne and rosacea",
      "validation_status": "FDA_APPROVED",
      "evidence": [
        "Doxycycline 40mg FDA approved for rosacea",
        "Inhibits cathelicidin pathway, MMPs, neutrophil chemotaxis",
        "Reduces IL-1beta, IL-6, TNF-alpha via NF-KB pathway"
      ],
      "hits_in_model": 9,
      "confidence": "high"
    },
    {
      "id": "crp_006",
      "atc_category": "R:respiratory",
      "disease_category": "dermatological",
      "drug_classes": ["H1 antihistamines"],
      "example_drugs": ["Levocetirizine", "Fexofenadine", "Cetirizine"],
      "mechanism": "H1 receptor blockade reduces pruritus in urticaria and atopic dermatitis",
      "validation_status": "VALIDATED_TRIALS",
      "evidence": [
        "Cetirizine effective for urticaria and atopic eczema pruritus",
        "Fexofenadine 120mg shows moderate benefit in atopic dermatitis",
        "Standard treatment for chronic spontaneous urticaria"
      ],
      "hits_in_model": 8,
      "confidence": "high"
    },
    {
      "id": "crp_007",
      "atc_category": "H:systemic_hormonal",
      "disease_category": "dermatological",
      "drug_classes": ["Corticosteroids"],
      "example_drugs": ["Prednisone", "Cortisone"],
      "mechanism": "Anti-inflammatory effects on skin inflammation; used for severe dermatological conditions",
      "validation_status": "FDA_APPROVED",
      "evidence": [
        "Systemic corticosteroids used for severe eczema, psoriasis flares",
        "Bridge therapy while disease-modifying agents take effect"
      ],
      "hits_in_model": 12,
      "confidence": "high"
    },
    {
      "id": "crp_008",
      "atc_category": "N:nervous_system",
      "disease_category": "autoimmune",
      "drug_classes": ["Local anesthetics"],
      "example_drugs": ["Lidocaine", "Bupivacaine"],
      "mechanism": "Nerve block for pain management in autoimmune conditions; NOT disease-modifying",
      "validation_status": "SYMPTOMATIC_ONLY",
      "evidence": [
        "Lidocaine patch used for localized pain in arthritis",
        "Intra-articular lidocaine abolishes peripheral nociceptive input",
        "Not indicated as disease-modifying therapy"
      ],
      "hits_in_model": 10,
      "confidence": "medium"
    },
    {
      "id": "crp_009",
      "atc_category": "D:dermatologicals",
      "disease_category": "autoimmune",
      "drug_classes": ["Topical agents", "Salicylates"],
      "example_drugs": ["Salicylic acid", "Topical steroids"],
      "mechanism": "Keratolytic and anti-inflammatory effects; used in psoriasis (autoimmune skin disease)",
      "validation_status": "FDA_APPROVED",
      "evidence": [
        "Salicylic acid is first-line for psoriasis scales",
        "Topical corticosteroids are mainstay of psoriasis treatment",
        "Psoriasis is classified as autoimmune"
      ],
      "hits_in_model": 9,
      "confidence": "high"
    },
    {
      "id": "crp_010",
      "atc_category": "D:dermatologicals",
      "disease_category": "infectious",
      "drug_classes": ["Corticosteroids"],
      "example_drugs": ["Dexamethasone", "Prednisolone"],
      "mechanism": "Reduces inflammation in severe infections; used adjunctively with antimicrobials",
      "validation_status": "VALIDATED_TRIALS",
      "evidence": [
        "Dexamethasone reduces mortality in severe COVID-19 (RECOVERY trial)",
        "Corticosteroids used in bacterial meningitis to reduce inflammation",
        "Must be combined with appropriate antimicrobial therapy"
      ],
      "hits_in_model": 5,
      "confidence": "high"
    },
    {
      "id": "crp_011",
      "atc_category": "V:various",
      "disease_category": "cancer",
      "drug_classes": ["Diagnostic radiopharmaceuticals"],
      "example_drugs": ["Fludeoxyglucose (18F)"],
      "mechanism": "PET imaging agent for cancer staging; detects metabolically active tumors",
      "validation_status": "FDA_APPROVED",
      "evidence": [
        "FDG-PET is standard for cancer staging and monitoring",
        "Detects increased glucose metabolism in malignancies"
      ],
      "hits_in_model": 6,
      "confidence": "high",
      "note": "Diagnostic, not therapeutic"
    }
  ],
  "usage_instructions": {
    "confidence_scoring": "Predictions matching high-confidence patterns can receive precision boost",
    "filters": "Patterns marked SYMPTOMATIC_ONLY should not boost disease-modifying predictions",
    "updates": "Add new patterns as validated through research"
  },
  "statistics": {
    "total_patterns": 11,
    "high_confidence": 10,
    "medium_confidence": 1,
    "fda_approved": 7,
    "validated_trials": 3,
    "symptomatic_only": 1
  }
}
